No Data
Aojing Healthcare: Aojing Healthcare: 2024 Annual Results Express Announcement
Aojing Healthcare: 2024 Annual Results Report Announcement
Aojing Medical (688613.SH) products have obtained registration certificates in Indonesia.
Gelonghui, February 18th丨Ao Jing Medical (688613.SH) announced that the company submitted the registration application materials for its artificial bone repair product to the Ministry of Health of Indonesia (referred to as "MOH") in December 2024. The company recently received a notification from MOH, stating that the artificial bone repair product has been approved by MOH. The BonGold artificial bone repair material, which obtained the registration certificate in Indonesia, is a bionic mineralized collagen artificial bone repair material developed and produced based on Ao Jing Medical's completely independent intellectual property rights in vitro biomimetic mineralization technology. It is designed to be similar to human compositions and microstructures.
Ojing Healthcare: 2024 Earnings Forecast Loss Announcement
Aojing Medical (688613.SH): Expected loss of 17.5559 million yuan in 2024.
On January 24, Gelonghui announced that Ao Jing Medical (688613.SH) released a preliminary loss announcement for its 2024 annual performance. According to initial calculations by the financial department, it is expected to achieve a revenue of 205.6091 million yuan in 2024, with a net income attributable to the owners of the parent company of -17.5559 million yuan, indicating a loss. Additionally, compared to a net income attributable to the owners of the parent company of 54.2318 million yuan (legally disclosed data) from the previous year, it is expected to decrease by 71.7877 million yuan, representing a year-on-year decline of 132.37%. Initial calculations by the financial department also suggest that it is expected to achieve net income in 2024.
Allgens Medical Technology CO., LTD.'s (SHSE:688613) Popularity With Investors Is Under Threat From Overpricing
Declining Stock and Decent Financials: Is The Market Wrong About Allgens Medical Technology CO., LTD. (SHSE:688613)?